INTRODUCTION
Allergic asthma is a Th2 lymphocyte-mediated inflammatory airway disease. It is characterized by airway eosinophilia, increased mucus production by goblet cells, and structural remodeling of the airway wall, leading to airway obstruction and airway hyperreactivity (AHR) to nonspecific stimuli. Allergy affects 300 million individuals worldwide and its prevalence has dramatically increased in the recent decades, most probably as a result of changes in environmental factors including reduced exposure to microbial antigens during infancy. Reduced risk of atopy has been linked to increased numbers of older siblings, early day-care attendance, agrarian lifestyle, early-life measles, and enteric infections. 1,2 Accordingly, infection with various parasites prevents the development of allergic airway inflammation in mice. 3 -5 These observations support the hygiene hypothesis that states that early exposure to pathogens provides protective effects, possibly through the activation of innate immune responses and / or the development of regulatory T cells (T reg ).
Along the same lines, an inverse correlation between exposure to food-borne microbes and respiratory allergy has pointed toward a role for the gut and gut-associated lymphoid tissue in shaping the immune response against environmental antigens. 6, 7 Furthermore, the intestinal bacterial flora was demonstrated to alter the mechanisms that are responsible for oral tolerance induction in mice. 8 For example, although oral administration of ovalbumin (OVA) abrogates both Th1 and Th2 responses in specific pathogen-free mice, only Th1 responses are reduced in germ-free mice. The reconstitution of intestinal flora of germ-free mice with Bifidobacterium infantis , one of the predominant bacteria in the intestinal flora, restored the susceptibility of these Th2 responses to oral tolerance induction. In addition, oral administration of live Lactobacillus reuteri to specific pathogen-free mice prevented allergic airway inflammation via the induction of T reg . 9, 10 This latter finding and potential problems arising upon parenteral administration of live microorganisms have resulted in a renewed interest in the possible modulation of the immune
The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways To investigate whether BV could prevent allergic airway inflammation in mice, BALB / c mice were treated daily with BV (25 mg orally) or with the vehicle control for 15 consecutive days. Mice were sensitized with two intraperitoneal (i.p.) injections of the Leishmania major antigen LACK in the Th2 adjuvant aluminum hydroxide and challenged 5 times 10 days later with LACK, or phosphate-buffered saline (PBS) aerosols ( Figure 1a ). Compared with LACK-sensitized and PBS-challenged mice, LACK-sensitized and -challenged mice treated with the vehicle exhibited the expected increased AHR to the nonspecific stimulus methacholine ( Figure 1b ), airway eosinophilia ( Figure 1c ), peribronchial and perivascular cellular infiltration of the lungs ( Figure 1d ), and mucus hypersecretion ( Figure 1d and e ). Administration of BV to LACK-sensitized and -challenged mice resulted in reduced AHR ( Figure 1b ) , fourfold less eosinophils ( P < 0.0001) and twofold less lymphocytes ( P = 0.017) in the bronchoalveolar lavage fluids (BALFs; Figure 1c ). Cellular infiltration of the lungs and mucus hypersecretion were also strongly decreased ( Figure 1d, e ) .
Compared with PBS-challenged animals, vehicle-treated mice challenged with LACK exhibited the expected cardinal features of allergic asthma, including higher numbers of CD4 + cells expressing the Th2-specific marker T1 / ST2 in BALF and lungs ( Figure 2a ), increased levels of interleukin (IL)-4, IL-5, IL-6, IL-10, IL-13, eotaxin (CCL11), and very low to undetectable levels of interferon-(IFN-) in lungs ( Figure 2b ), increased serum levels of LACK-specific immunoglobulin (Ig)G1 and IgE ( Figure 2c ), and similar low levels of LACK-specific IgG2a. In these animals, we found that BV treatment resulted in sixand three-fold less T1 / ST2 + CD4 + T cells in BALF and lungs, respectively ( Figure 2a ), and two-to five-fold less IL-4, IL-5, IL-6, IL-10, IL-13, and eotaxin in lungs ( Figure 2b ). IFNlevels were close to the lower limit of detection and remained similar in the two groups (data not shown). Although BV-and vehicle-treated mice exhibited similar serum levels of LACKspecific IgG1 and IgG2a ( Figure 2c ), BV-treated mice exhibited reduced serum levels of LACK-specific IgE ( Figure 2c ). In order to investigate whether BV-induced protection lasted over time, BV-treated mice that have previously undergone an acute episode of asthma were re-challenged with LACK aerosols 3 weeks later. In that case, no protection was observed, demonstrating that BV-induced suppression was short lived ( Supplementary Figure S1 online ) .
In order to demonstrate that the observed effects were not model dependent, we investigated whether BV protected mice from allergic airway inflammation induced by a different antigen. To this aim, BALB / c mice were treated with BV or vehicle as previously described, sensitized with OVA, and challenged with OVA or PBS. As observed in LACK-sensitized andchallenged mice, BV-treated OVA-sensitized and -challenged animals exhibited reduced AHR ( Supplementary Figure 2a Figure 2d online ) . Therefore, the protection from allergic airway disease that was induced by BV was not restricted to LACK-induced allergic asthma. BVinduced protection was also observed in C57BL / 6 mice and was dose dependent (data not shown, and Supplementary  Figure 3 online ).
BV-induced protection requires the adaptor MyD88
BV is composed of bacterial extracts. As bacteria express pathogen-associated molecular patterns that bind Toll-like receptors (TLRs), we next sought to investigate whether the ability of BV to protect against allergic airway inflammation required TLR signaling. To this aim, we first used MyD88 (myeloid differentiation primary response gene (88)) knockout (KO) mice that are deficient in the adaptor protein that is used by nearly all TLRs and IL-1R to activate the transcription factor nuclear factor-B. These mice have been shown to develop similar Th2 responses upon OVA sensitization in aluminum hydroxide, and airway inflammation upon OVA challenge. MyD88 KO mice were treated with BV or vehicle, and sensitized and challenged with LACK. In contrast to what was observed in wild-type (WT) mice, vehicle-and BV-treated MyD88 KO mice exhibited similar numbers of total cells, eosinophils, and lymphocytes in BALF ( Figure 3a ) and identical levels of IL-4, IL-5, and IL-13 in lungs ( Figure 3b ). These results suggested that the ability of BV to inhibit allergic airway inflammation was dependent on MyD88. To determine whether MyD88 was required for IL-1 or TLR signaling, we have treated WT mice with the commercialized ARTICLES IL-1R antagonist Kineret. In agreement with data obtained in IL-1R-deficient mice, 18 treatment of WT mice with Kineret did not modify AHR and airway inflammation in vehicle-treated mice. Most importantly, Kineret treatment did not prevent BVinduced protection from asthma ( Figure 3c, d ). Altogether, our results suggest that BV-induced protection requires TLR signaling.
BV induces an increase in the number of T reg in the trachea CD4 + T reg prevent the development of allergic asthma in both humans and mice. To monitor any T reg changes upon BV treatment, we used DEREG mice that express a diphtheria toxin receptor-enhanced green fluorescent protein (GFP) fusion protein under the control of the foxp3 gene locus, as reporter mice. 19 Naive DEREG mice were treated for 15 days with either BV or vehicle and the presence of GFP + CD4 + cells was monitored in various lymphoid and nonlymphoid organs. The cellularity in all the analyzed organs remained similar in both BV-and vehicle-treated mice (data not shown). However, although the frequency of GFP + CD4 + T cells was similar in BV-and vehicletreated mice in all tested secondary lymphoid organs, including the mesenteric lymph node (LN) and the spleen, BV-treated mice exhibited a twofold increased frequency of GFP + CD4 + T cells in the trachea when compared with vehicle-treated animals ( Figure 4a ). A more modest but significant increase in the frequency of GFP + CD4 + T cells was observed in the vagina and the intestinal lamina propria (LP) upon treatment with BV ( Figure 4a ). Most of GFP + CD4 + cells were stained with an antibody reacting to the T cell receptor (TCR) chain, but not with a GalCer / CD1d tetramer or an antibody reacting to the TCR receptor, suggesting that they were bona fide CD4 + T reg ( Figure 4b ). In addition, in both BV-and vehicle-treated mice, all GFP + CD4 + cells expressed GITR (glucocorticoid-induced tumor necrosis factor receptor), and 30 % expressed high levels of CD25 ( Figure 4b ). The frequency of GFP + CD4 + cells that expressed CTLA-4 (cytotoxic T-lymphocyte antigen 4) was higher in BV-treated mice when compared with vehicle-treated animals (21 vs. 8 % ; Figure 4b ). In addition, GFP + T reg from BVtreated mice and vehicle-treated mice were comparably able to inhibit T-cell proliferation ( Figure 4c ). In agreement with the In contrast, the frequency of IL-10-secreting cells increased from 13.9 ± 3.6 % in vehicle-treated mice to 26.3 ± 3.3 % in BV-treated animals ( P = 0.003). Therefore, when compared with vehicletreated mice, the trachea and other mucosal tissues of BV-treated animals contained an increased number of IL-10-secreting T reg with suppressive activity.
BV induces the conversion of Foxp3 − into Foxp3 + CD4 + lymphocytes
Although " natural " Foxp3 + T reg arise and mature in the thymus, peripheral conversion of Foxp3 − CD4 + T cells into Foxp3 + T reg has been observed in the intestinal LP and gut-associated lymphoid tissues after oral exposure to antigen. 20 These inducible T reg are believed to mediate peripheral T-cell tolerance to antigens derived from the diet and the commensal flora. To investigate whether BV promoted the conversion of FoxP3 − into FoxP3 + CD4 + cells, GFP − CD4 + T cells were purified from the spleen of naive DEREG mice and injected into recipient mice that were then orally treated with either BV or vehicle. Although GFP + cells were present at very low frequency or were undetectable in the spleen, peripheral LN, and mesenteric LN, they were readily detected in the trachea of BV-treated but not of vehicle-treated animals ( Figure 5a ). Therefore, the increased number of FoxP3 + CD4 + cells that were present in the airway mucosa of BV-treated animals resulted, at least in part, from the BV-induced conversion of FoxP3 − CD4 + cells into FoxP3 + CD4 + cells. To investigate whether the T reg that accumulated in the airway mucosa of BV-treated mice originated from LN, DEREG mice were injected i.p. every 3 days with the drug FTY720 that blocks the egress into the medullary sinus of LNs and efferent lymphatics, 21 -23 and were then treated or not with BV for 15 days. As previously observed, BV induced a 2 -3-fold increase in the frequency of GFP + CD4 + cells in the trachea, but not in the spleen or in the mesenteric LN ( Figure 5b ). However, this increase was abolished when mice were treated with FTY720, further suggesting that the GFP + CD4 + cells that accumulated in the trachea in BV-treated mice had migrated from the LN. Furthermore, a slight but significant increase in the frequency of GFP + CD4 + cells was observed in the mesenteric LN of BVtreated mice upon FTY720 treatment, suggesting that the T reg that were present in the trachea of BV-treated mice derive from the mesenteric LN. 
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Mesenteric LN of BV-treated mice exhibit an increased number of CD103 + DCs that drive Foxp3 + T-cell differentiation
In both mice and humans, CD103 + dendritic cells (DCs) that originate from the intestinal LP have been shown to imprint CD4 + T cells to specifically express the gut homing receptor CCR9, and to enhance T reg differentiation. 24 -27 Therefore, we hypothesized that T reg that accumulated in the trachea as the result of BV treatment might have been generated by the CD103 + MesLN DCs. To test this hypothesis, we measured the number and analyzed the phenotype of CD103 + DCs in the MesLN of BV-and vehicle-treated mice. Although the frequency of CD103 − DCs was similar in both groups, the frequency and number of CD103 + DCs were increased in BV-treated mice when compared with vehicle-treated animals ( Figure 6a, b ) . CD103 + DCs from vehicle-and BV-treated mice expressed similar levels of CD40, CD80, CD86, and major histocompatibility complex class II molecules ( Figure 6c ). To investigate whether 
BV-induced protection is mediated by a subset of CD4 + T cells expressing CCR9
We next investigated whether the inhibition of allergic asthma induced by BV was mediated by T reg . CD4 + T cells were purified from the trachea of BV-or vehicle-treated mice and injected into LACK-sensitized mice that were then challenged with LACK aerosols. Compared with recipient mice injected with CD4 + T cells from vehicle-treated mice, animals injected with CD4 + T cells from BV-treated mice exhibited decreased AHR ( Figure  7a ), reduced numbers of eosinophils and lymphocytes in BALF ( Figure 7b ), reduced numbers of T1 / ST2 + CD4 + T cells in BALF and lungs ( Figure 7c ) , and a 50 % reduction in the IL-5 and IL-13 levels in lungs ( Figure 7d ). Therefore, CD4 + T cells from BV-treated mice, but not those from vehicle-treated animals, could protect recipient mice from allergic airway inflammation upon adoptive transfer.
We have found that BV treatment induced a selective accumulation of CCR9-expressing T reg in the airway mucosa ( Figure 4e ). In an attempt to identify the subset of T reg that accounted for the ability of BV to protect from allergic airway disease, CD4 + T cells from the trachea of BV-or vehicle-treated mice were depleted of CCR9-positive cells before injection into LACK-sensitized recipients. Mice were then challenged with LACK aerosols and analyzed for the cardinal features of asthma. In contrast to what was observed with nondepleted CD4 + population, mice injected with CCR9-depleted CD4 + T cells from BV-treated mice and those injected with CCR9-depleted CD4 + T cells from vehicle-treated mice exhibited similar AHR ( Figure 7a ), similar number of eosinophils in BALF ( Figure 7b ), as well as similar numbers of T1 / ST2 + CD4 + T cells in BALF and lungs ( Figure 7c ) and comparable levels of IL-5 and IL-13 cytokines in lungs ( Figure 7d ). These results suggested that the ability of BV to induce protection was mediated by a subset of T reg expressing CCR9.
IL-10 is critical to control airway inflammation but not AHR
As 20 -25 % of BV-induced T reg secreted IL-10 ( Figure 4g ), we investigated whether BV-induced protection was dependent on IL-10. To this aim, vehicle-and BV-treated LACK-sensitized mice were treated or not with anti-IL-10R monoclonal antibody (mAb) during aerosol challenges. AHR was not affected by antibody treatment in both groups ( Figure 8a ). In sharp contrast, although anti-IL-10R mAb treatment did not affect the airway inflammation in vehicletreated mice, BV-treated mice were not protected and exhibited similar numbers of eosinophils and lymphocytes in BALF ( Figure 8b ). In addition, upon treatment with anti-IL-10R mAb, the number of Th2 cells in both BALF and lungs and the amounts of cytokines in lungs were similar in both vehicle-and BV-treated mice ( Figure 8c, d ) . Therefore, although AHR was unaltered by IL-10R blockade, the protection conferred by BV against airway inflammation was dependent on IL-10.
DISCUSSION
In this study we have demonstrated that oral administration of the bacterial lysate BV inhibited AHR, lung inflammation, mucus hypersecretion, airway eosinophilia, and production of antigen-specific IgE in antigen-sensitized and -challenged mice. The number of Th2 cells in BALF and lungs of BV-treated mice was strongly decreased, and lung contents in IL-4, IL-5, IL-6, IL-10, IL-13, and eotaxin were dramatically reduced. In apparent contrast to published results in which BV increased systemic Th1 responses in OVA-immunized mice, 28 we found that IFNlevels in lungs remained very low and similar in BV-treated and vehicle-treated mice.
BV is an extract made of several strains of G + and G − pneumotropic bacteria that consists mainly of acidic proteins, peptides, 
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and amino acids, and also traces of minor components such as sugar fatty acids, and detoxified lipopolysaccharides and lipoteichoic acids. Although we have shown that MyD88 but not IL-1 signaling was required in BV-induced protection, our preliminary data using TLR2 / 4-double KO mice suggest that neither TLR2 nor TLR4 were necessary for BV-induced protection (data not shown). It remains to be determined which TLR is necessary for BV-induced protection against asthma. Oral administration of BV induced an increase in the frequency and number of FoxP3 + T reg in the intestinal LP, the airway mucosa, and to a smaller extent in the vagina, but not in secondary lymphoid organs. Our data are in agreement with the concept of the common mucosal immune system, in which the presentation of an antigen at one mucosal site may lead to stimulation of an immune response at a distant mucosal tissue. Transcutaneous, oral, and nasal immunizations can induce immune responses at the gastrointestinal, reproductive, and respiratory surfaces. 29 -32 This could be explained by the selective expression of chemokine receptors or integrins by effector cells. For example, nasal immunization induces the expression of high levels of CCR10 and 4 1 integrin by IgA-producing plasma cells, allowing them to migrate to the respiratory and genitourinary tracts that express their corresponding ligands, CCL28 (chemokine (C-C motif) ligand 28) and VCAM1 (vascular cell adhesion molecule-1). 33, 34 In contrast, orally induced IgA-producing B cells express CCR9 and CCR10, as well as 
4 7 and 4 1 integrins, and hence they migrate to sites such as the small intestine and the airways, which express CCL25 and CCL28 together with MADCAM1 (mucosal vascular addressin cell adhesion molecule 1) and / or VCAM1. 34 One important result in this study is the demonstration that a bacterial extract given orally leads to a specific increase in T reg in the respiratory tract. Interestingly, Strickland et al. 35 showed that prevention of T-cell activation and AHR during chronic allergen exposure of sensitized rats was mediated by T reg localized in the airway mucosa. The location of these T reg is critical to inhibit memory T helper cell-mediated upregulation of airway mucosal DCs, and their subsequent migration to the lung-draining LN.
As T reg in the trachea of BV-treated mice expressed high levels of CCR9, they were likely to be of intestinal origin, as only DCs from mesenteric LN and Peyer ' s patches have been shown so far to imprint a CCR9 phenotype on lymphocytes. Initial studies have demonstrated that adoptively transferred TCR transgenic CD4 + and CD8 + T cells primed in the mesenteric, but not cutaneous LNs or spleen, expressed high levels of the 4 7 integrin and CCR9. 36 Subsequently, it was shown that T cells primed in vitro with antigen-pulsed mesenteric LN or Peyer ' s patch DCs, but not with DCs from the spleen or peripheral LN, expressed CCR9 and high levels of 4 7 . 37, 38 We have shown that FTY720 administration prevented T reg from accumulating in the trachea as the result of BV treatment and resulted in an increase in the number of T reg in the mesenteric LN. Altogether, these results suggest that BV promotes the development of T reg in the mesenteric LN and that these cells have the ability to relocalize in the airways. It remains to be determined whether CCR9 is required for their homing to the trachea. However, although the lungs of asthmatic patients express high levels of CCL25 that promotes the recruitment of the CCR9 + V 24 invariant natural killer T cells, 39 the lungs of naive mice express very low levels of CCL25, 36 making unlikely the involvement of CCR9 in the homing of T reg into the trachea. 
Mice injected with GFP − CD4 + T cells from DEREG mice and further fed with BV exhibited GFP + CD4 + T cells in trachea, demonstrating that BV treatment induces the conversion of FoxP3 − CD4 + T cells into FoxP3 + CD4 + T cells. Although it is still unclear which cells induce the conversion of FoxP3 − into FoxP3 + CD4 + T cells, we found that the mesenteric LN of BV-treated animals contained twofold more CD103 + DCs than those from vehicle-treated mice. As previously reported for CD103 + DCs from naive WT mice, these DCs were capable of inducing FoxP3 + CD4 + T cells. Therefore, it is very likely that the increased number of CD103 + DCs induced by BV is responsible for the increased numbers of T reg that accumulated in the trachea as the result of BV treatment.
The role of T reg in BV-induced protection was demonstrated by the transfer of CD4 + T cells purified from the airway mucosa of BV-treated mice into sensitized mice. Although the transfer of total CD4 + T cells into sensitized mice from BV-treated mice led to protection, injection of CCR9-depleted CD4 + T cells did not, demonstrating that a particular subset of CCR9-expressing T reg has the ability to suppress allergic airway inflammation. 
Interestingly, it has been shown in healthy individuals that circulating CCR9 + CD4 + T cells with a memory phenotype exhibit characteristics of mucosa T cells and that some of them are T regulatory type 1-like cells. 41 In agreement with this finding, we found that > 20 % of trachea T reg in BV-treated mice produced IL-10. Most importantly, we showed that BV-induced protection from airway inflammation was dependent on IL-10. This cytokine has been shown to be essential for the suppression of airway inflammation in several mouse models as well as in immunotherapy in humans. 42 -46 Although it remains to be confirmed whether BV-induced protection is dependent on IL-10 produced by T reg , it is noteworthy that the deletion of IL-10 in T reg promoted allergic airway inflammation. 47 Altogether, our results show that oral treatment with BV suppresses the cardinal features of asthma via the induction of IL-10-producing CCR9 + T reg .
This study provides evidence for the use of BV as a safe, ready, and efficient treatment in children to prevent the development of allergic diseases.
METHODS
Animals
. BALB / c ByJ mice (6 weeks old) were purchased from the Centre d ' Elevage Janvier, France. LACK TCR transgenic mice (WT15 RAG-1 KO) and MyD88 KO mice 48 on the BALB / c background, and DEREG mice 19 on the C57BL / 6 background, were bred in our animal facility at the Institut de Pharmacologie Mol é culaire et Cellulaire (Valbonne, France). All experimental protocols were approved by the local animal ethics committee.
Reagents . BV was made of extracts from H. influenzae , D. pneumoniae , K. pneumoniae , K. ozaenae , S. aureus , S. pyogenes , S. viridans , and N. catarrhalis . LACK recombinant protein was produced in Escherichia coli and purified as described 49 and detoxified using Endotrap (Profos, Regensburg, Germany). Lipopolysaccharide contents in LACK protein samples were < 5 ng mg -1 as determined using a Limulus Amoebocyte Lysate (LAL) assay (Pierce; Perbio Science, Brebieres, France). T1 / ST2 mAbs were purchased from MD Biosciences (Zurich, Switzerland). Monoclonal antibodies to CD4, CD25, TCR V , CD103, CTLA-4, GITR, and TCR were purchased from BD Biosciences (Le Pont de Claix, France). Antibodies to 4 7 , CCR9, and CCR10 were purchased from eBiosciences (Paris, France). CD1d tetramers and PBS-57, an analog of -galactosylceramide, were obtained from the NIH tetramer core facility (Bethesda, MD). Anti-IL-10R mAb (1B1.2 clone) is a kind gift of DNAX Research Institute (Palo Alto, CA). LACK 156 − 173 peptide was purchased from Mimotopes (Victoria, Australia).
Experimental asthma and treatments . Mice were sensitized by two i.p. injections of 10 g of LACK (or OVA (Profos)) in 2 mg of aluminum hydroxide (Pierce) at days 0 and 7. At days 17 -21, sensitized mice were exposed to LACK (1.5 mg ml -1 ) or OVA (2 mg ml -1 ) aerosols for 20 min using an ultrasonic nebulizer (AeroNeb; Emka Technologies, Paris, France). BV-treated and vehicle-treated mice were every day administered 25 mg of BV in 500 l of water or 500 l of water only (vehicle), respectively. Treatment started at day − 1 and stopped at day 14. In some experiments, mice were treated i.p. with the IL-1R antagonist Kineret (Biovitrum AB, Stockholm, Sweden) at 150 mg kg -1 every day from day − 1 to day 16. In the indicated experiments, mice were treated i.p. with FTY720 (Cayman, Interchim, Montigny, France) at 1 mg kg -1 every 3 days for 15 days. Neutralization of IL-10R was performed by i.p. injection of 0.5 mg of anti-IL-10R mAbs every other day starting at day 16 until day 20.
Antibody titers . Mice were bled one day after the last aerosol. LACK-and OVA-specific IgG1, IgG2a, and IgE were measured by enzyme-linked immunosorbent assay using specific mAbs purchased from BD Biosciences as previously described. 50 Number and phenotype of BALF cells . Mice were bled and a canula was inserted into the trachea. Lungs were washed three times with 1 ml of PBS. For differential BAL cell counts, cells were stained with mAb anti-CCR3 (R & D), anti-Gr1, anti-CD3, and anti-CD19 mAbs (BD Biosciences) and analyzed by fluorescence-activated cell sorting (FACS) using a FACScalibur flow cytometer and Cellquest software. Eosinophils were defined as CCR3 + CD3 − CD19 − , neutrophils as Gr-1 high CCR3 − CD3 − CD19 − , lymphocytes as CD3 + CD19 + , and alveolar macrophages as large autofluorescent cells.
Airway hyperreactivity . One day after the last LACK aerosol challenge, AHR was measured by either whole-body or invasive plethysmo graphy (Emka Technologies) in response to inhaled methacholine (Sigma, Lyon, France) as described previously. 51 For dynamic lung resistance and compliance, measurements were performed using a Flexivent apparatus (SCIREQ; Emka Technologies). Mice were anesthetized (5 ml per kg body weight (ml kg -1 ) of 10 % medetomidine (Dormitor; Pfizer, Paris, France) and 10 % ketamine (Imalgene; Merial, Lyon, France)), tracheotomized, paralyzed (5 ml kg -1 pancuronium bromide 1 % (Pavulon; Organon, Puteaux, France)), and immediately intubated with an 18-gauge catheter, followed by mechanical ventilation. Respiratory frequency was set at 150 breaths per min with a tidal volume of 0.2 ml, and a positive-end expiratory pressure of 2 ml H 2 O was applied. Increasing concentrations of methacholine (0 -50 mg ml -1 ) were administered at the rate of 20 puffs per 10 s, with each puff of aerosol delivery lasting 10 ms, via a nebulizer aerosol system with a 2.5 -4 m aerosol particle size generated by a nebulizer head (Aeroneb; Aerogen, Emka Technologies). Baseline resistance was restored before administering subsequent doses of methacholine.
Histology . Lung samples were harvested and treated as described previously. 52 Sections (4 m) were performed and stained with May Gr ü nwald Giemsa for morphology or with periodic acid Schiff for detection of mucopolysaccharide accumulation as described previously. 52 Mucus index was calculated, and analyzed using Image J software (NIH, Bethesda, MD) as follows: (average intensity of epithelial periodic acid Schiff staining) × (area of epithelial periodic acid Schiff staining) × (total area of conducting airways).
Cytokine measurement . Lung samples were homogenized in calciumand magnesium-free Hanks balanced salt solution. Multiplex IL-4, IL-5, IL-6, IL-10, IL-13, and IFN-analyses were performed with cytometric bead array using FACS array (BD Bisociences). Eotaxin levels were measured by enzyme-linked immunosorbent assay using its pairs from BD Biosciences.
Cell preparations . LN, spleen, trachea, lung, or vagina were cut to small pieces in Hanks balanced salt solution containing 400 U type I collagenase and 1 mg ml -1 DNAse I and digested for 30 min at 37 ° C. Cells were strained through a 70-m cell strainer, and erythrocytes were lysed with ACK lysis buffer. Intestinal LP cells were obtained after digestion of the small intestine in RPMI containing fetal calf serum 5 % , 5 m M EDTA, and 2 m M dithiothreitol as described previously. 53 Briefly, the small intestines were minced after the removal of the Peyer ' s patches. The pieces were incubated under agitation in the digestion buffer for 30 min and filtered. The retained fraction was further digested in RPMI containing fetal calf serum 5 % , 400 U of type I collagenase, and 0.1 mg ml -1 of DNase I, and filtered after a 30-min incubation period. Both flow through were centrifuged and stained for cytometry analysis.
Suppression assay . GFP + CD4 + cells from DEREG mice cells were enriched by positive selection using CD4-coated magnetic beads
